Nevertheless, further elucidation of the precise molecular mechanisms involved and rigorous translational studies are warranted to ascertain the clinical implications and therapeutic viability of JMJD3 modulation in AAA management [30]. The gene discussed is KDM6B; the disease is triple-A syndrome.